Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 14/20 | 0.70 |
| ▸ | ATR | Q13535 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951276 | 0.92 | FLT3 (0.62) | FLT3ATRMEN1KMT2AFGFR1 | |
| SCHEMBL5952456 | 0.92 | CHEK1 (0.66) | FLT3ATRMEN1KMT2AFGFR1 | |
| SCHEMBL1224541 | 0.91 | FLT3 (0.61) | FLT3FGFR1FLT1CHEK1PDPK1 | |
| SCHEMBL13373641 | 0.90 | FGFR1 (0.68) | FLT3ATRMEN1KMT2AFGFR1 | |
| SCHEMBL1224994 | 0.90 | FLT3 (0.60) | FLT3FGFR1FLT1CHEK1PDPK1 | |
| SCHEMBL31172406 | 0.88 | FLT3 (0.73) | FLT3 | |
| SCHEMBL31172173 | 0.88 | FLT3 (0.65) | FLT3FGFR1FLT1CHEK1PDPK1 | |
| SCHEMBL31172237 | 0.88 | PDPK1 (0.61) | FLT3FGFR1FLT1CHEK1PDPK1 | |
| SCHEMBL1225650 | 0.88 | FLT3 (0.57) | FLT3FGFR1FLT1CHEK1PDPK1 | |
| SCHEMBL1225812 | 0.88 | PDPK1 (0.61) | FLT3FGFR1FLT1CHEK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464231-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | Epitherix, LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | FLT3 1964/4885ATR 3684/4885MEN1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.